Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2Recruiting 1Not yet recruiting 1Completed 1Approved for marketing 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 7Lymphoma, Non-Hodgkin 6Lymphoma, B-Cell 6Hematologic Diseases 5Lymphoma, Mantle-Cell 3Waldenstrom Macroglobulinemia 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Multiple Myeloma 1

Interventions

Rituximab 6ibrutinib 4venetoclax 3acalabrutinib 3zanubrutinib 2pirtobrutinib 2fludarabine phosphate 2Whole-Body Irradiation 2Sirolimus 2Mycophenolic Acid 2Melphalan 2Cyclophosphamide 2Bortezomib 2Bendamustine Hydrochloride 2selinexor 1loncastuximab tesirine 1ixazomib 1carfilzomib 1Valganciclovir 1Valacyclovir 1Therapeutics 1Tacrolimus 1Polymerase Chain Reaction 1Pharmacogenomic Testing 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Methotrexate 1Lenalidomide 1Ganciclovir 1Foscarnet 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Waldenstrom Macroglobulinemia × pirtobrutinib × Clear all
NCT05734495 2026-05-28

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
46 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05024045 2026-03-03

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Eli Lilly and Company

Phase 1 Active not recruiting
316 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡